(Q52565553)

English

Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: Results from a phase 1 study.

scientific article published on 24 April 2018

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Andecaliximab/GS-5745 alone and combined with mFOLFOX6 in advanced gastric and gastroesophageal junction adenocarcinoma: Results from a phase 1 study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

gastroesophageal junction adenocarcinoma

0 references

Heinz-Josef Lenz

16

object named as

Heinz-Josef Lenz

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

author name string

Manish A Shah

1

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Alexander N Starodub

2

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Sunil Sharma

3

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Jordan Berlin

4

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Manish R Patel

5

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Zev A Wainberg

6

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Jorge Chaves

7

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Michael S Gordon

8

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Kevin Windsor

9

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Carrie Baker Brachmann

10

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Xi Huang

11

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Greg Vosganian

12

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Julia D Maltzman

13

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Victoria Smith

14

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Jeffrey A Silverman

15

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Johanna C Bendell

17

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

language of work or name

0 references

publication date

24 April 2018

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Proteases as prognostic markers in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinases: their biological functions and clinical implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New approaches to prediction of immune responses to therapeutic proteins during preclinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Matrix metalloproteinases: regulators of the tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of Matrix Metalloproteinase‐9 mRNA and Vascular Endothelial Growth Factor Protein in Gastric Carcinoma and Its Relationship to Its Pathological Features and Prognosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pN0 gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of matrix metalloproteinase-9 in gastric cancer: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secretory pathways generating immunosuppressive NKG2D ligands: New targets for therapeutic intervention.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29691300

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-17-2469

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29691300

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52565553&oldid=1478279971"